Ind-Swift Labs Q4 revenue rises to ₹1.7B, net profit at ₹151.1M
Ind-Swift Laboratories Ltd. announced its Q4 FY26 results, reporting a revenue of ₹1.7 billion and a net profit of ₹151.1 million. The company achieved an EBITDA gain of ₹206 million, reversing a loss from the previous year. The board approved the audited financial results and re-appointed cost auditors for the upcoming fiscal year.

*this image is generated using AI for illustrative purposes only.
Ind-Swift Laboratories Ltd. has reported its consolidated financial results for the fourth quarter and financial year ended March 31, 2026. The company posted a revenue of ₹1.7 billion for the quarter, a year-on-year increase from ₹1.4 billion. Consolidated net profit stood at ₹151.1 million for the quarter ended March 31, 2026, compared to ₹2.22 billion in the prior-year period, which included an exceptional item of ₹2.16 billion.
Q4 Financial Highlights
The board of directors approved the audited financial results for the quarter and financial year ended March 31, 2026, at a meeting held on May 28, 2026. The company reported an EBITDA gain of ₹206 million for the quarter, a significant turnaround from a loss of ₹44 million in the same period last year, with an EBITDA margin of 12.12%. Profit before tax for the quarter was ₹171 million, compared to ₹146 million in the corresponding prior-year period.
The following table summarises the key consolidated financial metrics for the quarter:
| Metric: | Q4 Current | Q4 Previous (YoY) |
|---|---|---|
| EBITDA: | ₹206M (Gain) | ₹44M (Loss) |
| EBITDA Margin: | 12.12% | — |
| Revenue: | ₹1.7B | ₹1.4B |
| PBT: | ₹171M | ₹146M |
| Net Profit: | ₹151.1M | ₹2.22B* |
*Prior-year net profit included an exceptional item of ₹2.16 billion.
Operational and Regulatory Updates
The statutory auditors, M/s. Rattan Kaur & Associates, issued an unmodified opinion on the standalone and consolidated financial results. The board also re-appointed M/s. V. Kumar & Associates, Cost Accountants, as the cost auditors for the financial year 2026-27. The company noted that the amalgamation of Ind Swift Limited with the company became effective from August 8, 2025, and the financial results reflect the combined entity post-amalgamation.
Ind-Swift Laboratories is a pharmaceutical entity with manufacturing facilities located in Punjab and Jammu & Kashmir, with its registered office situated in Chandigarh.
Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE915B01019/0caa51a7-79d3-4bc3-b39e-79445884f4f1.pdf
Historical Stock Returns for Ind Swift Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +3.65% | +23.65% | +52.44% | +118.61% | +83.89% | +84.14% |
How will the amalgamation with Ind Swift Limited influence revenue growth and operational efficiency in FY2027?
What strategies are in place to sustain the EBITDA margin of 12.12% in the coming quarters?
Are there any upcoming regulatory approvals or product launches expected to drive future revenue?

































